The Neurofibromatosis-associated Tumor Biobank
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03359304|
Recruitment Status : Not yet recruiting
First Posted : December 2, 2017
Last Update Posted : December 2, 2017
|Condition or disease|
Samples of blood and other stored material such as slides,frozen tissues or leftover diagnostic material.
Questionnaire information, including health history, growth and development, physical activity and family medical history information.
If patients have been diagnosed with a neurofibromatosis-associated tumor or another condition the investigator is interested in， the investigator will ask the patient to release medical record information relating to diagnosis and treatment of neurofibromatosis-associated tumor, other cancers, blood disorders, and similar conditions.
|Study Type :||Observational|
|Estimated Enrollment :||300 participants|
|Official Title:||Establishment of Neurofibromatosis-associated Tumours Biobank for Future Genomic-based Research Aiming at Improved Outcome Prediction|
|Estimated Study Start Date :||March 1, 2018|
|Estimated Primary Completion Date :||March 1, 2023|
|Estimated Study Completion Date :||March 1, 2028|
- Detected NF-1 gene expression pattern in neurofibromatosis-asociated tumor [ Time Frame: 3 years ]To examine the neurofibromatosis type 1(NF-1) gene expression of the patients with neurofibromatosis-associated tumor
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03359304
|Contact: Kuisheng Liu, phDfirstname.lastname@example.org|
|Principal Investigator:||Tingting Ren, phD||Peking University People's Hospital|